Hepatitis A, B, and A/B vaccination series completion among US adults: A claims-based analysis

Ghaswalla, Parinaz; Patterson, Brandon J.; Cheng, Wendy Y.; Duchesneau, Emilie; Macheca, Monica; Duh, Mei Sheng

doi:10.1080/21645515.2018.1489189

Cited by 13 publications

(14 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 Retrospective studies have shown that completion rates of Hepatitis A and B vaccine series were typically low, ranging between 25% and 65% depending on the vaccine, age and payer type. 25 , 26 However, the target population for Hepatitis A and B (adults ≥19 years with additional risk factors or another indication) differs substantially from the target population of RZV, 27 which may explain the observed differences in completion rates. On the other hand, observed RZV US completion levels were below those seen for pediatric vaccines.…”

Section: Discussionmentioning

confidence: 99%

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

Patterson¹,

Chen

McGuiness

et al. 2021

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 in the United States (US) for the prevention of herpes zoster in adults aged 50 years and older. The vaccine is administered in two doses, with the second dose administration recommended between two and six months after the first dose. Examination of uptake and series completion is important to ensure appropriate use, especially at the time of vaccine introduction. This report provides demographic characteristics of patients receiving RZV between October 2017 and September 2019, first-and second-dose uptake, and a cumulative estimation of second-dose completion by month for US adults aged 50 years and older. Monthly uptake increased rapidly since October 2017; overall, 7,097,441 first doses of RZV were administered along with 4,277,636 second doses during the observed timeframe. Among people with an observed first-dose administration, 70% and 80% completed the two-dose series within six and 12 months post initial dose, respectively. This evidence suggests that RZV has rapidly been adopted by a large population in the US and most are following manufacturer or policy recommendations regarding series completion. Further analyses are needed to explore potential patient, provider, and policy-relevant characteristics associated with second-dose completion that could serve as targets for further improvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

Patterson¹,

Chen

McGuiness

et al. 2021

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…This would have provided a valuable comparison in rates of immunoprevalence and incident infections between tourists and residents, as well as the efficacy of the HAV vaccine and the effectiveness of global vaccination programs. Although information regarding hepatitis A vaccination series completion rates is limited, low HAV vaccine series completion rates were observed among cohorts of commercial/Medicare (32%) and Medicaid (21%) enrollees in the United States (38). Additionally, adherence with and completion of recommended hepatitis vaccination schedules among adults in the United States have been described as suboptimal, leaving a substantial proportion of adults at risk (39).…”

Section: Discussionmentioning

confidence: 99%

Rapid Salivary IgG Antibody Screening for Hepatitis A

et al. 2020

View full text Add to dashboard Cite

Hepatitis A virus (HAV) is a common infection that is transmitted through the fecal-oral route, shed in the stool of infected individuals and spread either by direct contact or by ingesting contaminated food or water. Each year, approximately 1.4 million acute cases are reported globally with a major risk factor for exposure being low household socioeconomic status. Recent trends show a decrease in anti-HAV antibodies in the general population, with concomitant increases in the numbers of HAV outbreaks. In line with a recreational water study, this effort aims to assess the prevalence of salivary IgG antibodies against HAV and subsequent incident infections (or immunoconversions) in visitors to a tropical beach impacted by a publicly owned treatment works (POTW). We applied a multiplex immunoassay to serially collected saliva samples gathered from study participants who recreated at Boquerón Beach, Puerto Rico. Analysis of assay results revealed an immunoprevalence rate of 16.17% for HAV with 1.43% of the cohort immunoconverting to HAV. Among those who immunoconverted, 10% reported chronic gastrointestinal symptoms and none experienced diarrhea. Tests on water samples indicated good water quality with low levels of fecal indicator bacteria, however, the collection and analysis of saliva samples afforded the ability to detect HAV infections in beachgoers. This rapid assay serves as a cost-effective tool for examining exposure to environmental pathogens and can provide critical information to policy makers, water quality experts and risk assessment professionals seeking to improve and protect recreational water and public health.

show abstract

“…The latter eligibility criterion served to evaluate vaccination series completion. However, this part of the analysis has been published elsewhere (Ghaswalla et al, 2018). A post-hoc sensitivity analysis was also conducted to describe the provider type and place of hepatitis A, B, or A/B vaccination among patients who met eligibility criteria 1) and 2) only, to ensure robustness of this analysis.…”

Section: Methodsmentioning

confidence: 99%

The role of provider characteristics on the hepatitis A and B vaccination status of adults in the United States during 2007–2015

Ghaswalla

Patterson

Cheng

et al. 2019

Preventive Medicine Reports

View full text Add to dashboard Cite

Hepatitis A and B vaccine coverage is suboptimal in US adults, even among those at increased risk for infection, morbidity, or mortality. To understand where medical education and resources might enhance vaccine coverage, it is important to first identify providers and places most commonly associated with the administration of hepatitis vaccinations. We conducted a retrospective analysis of commercial and Medicare insurance claims data from 2007 to 2015 to describe provider types and places of vaccination against hepatitis A and B among adults in the US, and estimated the time to initial vaccination from first diagnosis of a condition for which the Advisory Committee on Immunization Practices (ACIP) recommends hepatitis A and/or B vaccination among at-risk adults. We identified 183,326 adults who received hepatitis A vaccine, 148,119 hepatitis B vaccine, and 64,953 a bivalent vaccine. Mean age was 42.1–45.8 years. Family practice and internal medicine physicians were the main vaccine providers: 38.9% and 20.2% for hepatitis A, 43.7% and 21.4% for hepatitis B, 35.3% and 15.9% for bivalent vaccinations, respectively. ≥90% of initial vaccinations occurred in an office practice. In at-risk patients, median time to first-dose received was 11.8, 20.9, and 20.9 months for hepatitis A, hepatitis B, and hepatitis A/B vaccines, respectively. Primary care and office practices were the most common providers and places of vaccination, respectively, for hepatitis A and B vaccine. For at-risk patients, further research is needed to design vaccination strategies to improve the median time from first ACIP-recommended condition diagnosis to initial vaccination against hepatitis A and B.

show abstract

Hepatitis A, B, and A/B vaccination series completion among US adults: A claims-based analysis

Cited by 13 publications

References 20 publications

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

Rapid Salivary IgG Antibody Screening for Hepatitis A

The role of provider characteristics on the hepatitis A and B vaccination status of adults in the United States during 2007–2015

Contact Info

Product

Resources

About